By virtue of its differential expression, an antibody–drug conjugate targeting Nectin-4 (enfortumab vedotin) that delivers an anticancer agent to Nectin-4-expressing tumors has been developed for the treatment of bladder cancer patients49, 51. This evidence concerns the gene NECTIN4 and urinary bladder carcinoma.